Low serum Caveolin-1 levels were associated with a higher risk of cerebral microbleeds compared to high levels in patients with acute ischemic stroke (OR 4.05; 95% CI 1.77-9.30).
Observational (n=156)
Odds Ratio: 4.05 (95% CI 1.77–9.3)
Caveolin-1 (Cav-1) plays pivotal roles in the endothelial damage following stroke. The present study aimed to investigate whether serum Cav-1 level is associated with the presence of cerebral small vessel disease (cSVD) in patients with acute ischemic stroke. To this end, 156 patients were consecutively enrolled. Cranial magnetic resonance imaging was analyzed to determine the surrogates of cSVD, including cerebral microbleeds (CMBs), silent lacunar infarcts (SLIs), and white matter hyperintensities (WMHs). After adjusting for potential confounders, patients with low Cav-1 level had a higher risk of CMBs than patients with high Cav-1 level (OR: 4.05, 95% CI: 1.77-9.30). However, there was no relationship between Cav-1 and the presence of SLIs or WMHs. When CMBs were stratified by location and number, a similar association was found in patients with deep or infratentorial CMBs (OR: 4.04, 95% CI: 1.59-10.25) and with multiple CMBs (OR: 3.18, 95% CI: 1.16-8.72). These results suggest lower serum Cav-1 levels may be associated with CMBs, especially those that are multiple and located in deep brain or infratentorial structures, in patients with acute ischemic stroke. Cav-1 may be involved in the pathophysiology of CMBs, and may act as a potential target for treating cSVD.
Zhang et al. (Fri,) conducted a observational in acute ischemic stroke (n=156). Low serum Caveolin-1 level vs. High serum Caveolin-1 level was evaluated on presence of cerebral microbleeds (CMBs) (OR 4.05, 95% CI 1.77-9.30). Low serum Caveolin-1 levels were associated with a higher risk of cerebral microbleeds compared to high levels in patients with acute ischemic stroke (OR 4.05; 95% CI 1.77-9.30).